Sanofi India Limited — Updates, 27-02-2025: Press Release

**Financial Highlights:** Sanofi India Limited reported a net sales growth of 8% for Q4-2024, with standalone profit from operations reaching ₹108 crores, up from ₹90 crores year-on-year. Total income for Q4-2024 was ₹5,208 crores, while total expenses were ₹4,066 crores, leading to a profit before tax from continuing operations of ₹1,222 crores.

**Strategic Initiatives and Growth Drivers:** The company has successfully advanced its ‘India for India’ strategy through innovative go-to-market initiatives and operational efficiencies. The launch of Soliqua® has been positive, bolstering the diabetes portfolio, alongside partnerships aimed at strengthening presence in the CNS and cardiovascular segments.

**Business Developments:** The Board has proposed a final dividend of ₹117 per equity share, subject to shareholder approval at the upcoming AGM, reflecting strong confidence in financial performance.

**Market Position and Competitive Advantage:** Sanofi’s strategic focus on expanding its diabetes offerings and partnerships positions it well within the pharmaceutical market, enabling it to leverage growth opportunities effectively post-demerger of its consumer healthcare unit.

**Investor Implications:** Investors should note the company’s robust revenue growth and operational improvements, providing a positive outlook. The proposed dividend further signifies solid shareholder returns amidst strategic developments.